Last reviewed · How we verify
SC Tulisokibart
SC Tulisokibart is a subcutaneous immunotherapy agent designed to modulate immune responses, though its precise molecular mechanism requires further clarification.
At a glance
| Generic name | SC Tulisokibart |
|---|---|
| Also known as | PRA023, MK-7240 |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
As an investigational agent in Phase 3 development by Merck Sharp & Dohme, tulisokibart appears to function as an immunomodulatory therapy. The subcutaneous formulation suggests optimization for patient convenience and tolerability in chronic or repeated dosing scenarios, though the specific molecular target and detailed mechanism of action are not publicly well-characterized.
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) (PHASE3)
- A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) (PHASE2)
- Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) (PHASE2)
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) (PHASE3)
- Pharmacokinetic (PK) Characterization of Subcutaneous Tulisokibart (MK-7240-010) (PHASE1)
- Single Dose Study of Tulisokibart (MK-7240) in Healthy Chinese Participants (MK-7240-002) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC Tulisokibart CI brief — competitive landscape report
- SC Tulisokibart updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI